What is the most appropriate antiplatelet regimen for a patient who underwent PCI with a drug-eluting stent?

The most appropriate antiplatelet regimen for a patient who underwent percutaneous coronary intervention (PCI) with a drug-eluting stent typically involves dual antiplatelet therapy (DAPT) to prevent stent thrombosis and other thrombotic events. The recommended treatment usually includes aspirin in conjunction with another antiplatelet agent.

In this case, the option involving aspirin 81 mg daily combined with clopidogrel 75 mg daily for 6 months aligns with current guidelines that advocate for a standard duration of DAPT using aspirin and clopidogrel after drug-eluting stent placement. This regimen effectively reduces the risk of cardiovascular events while balancing the risk of bleeding that may accompany longer-term antiplatelet therapy.

In contrast, the other options either recommend an incorrect or excessive duration of DAPT based on the type of stent used, or they prescribe combinations that are not supported by the guidelines for drug-eluting stents. For instance, the option suggesting ticagrelor may indicate a shorter duration than what's generally recommended with drug-eluting stents, typically around 6-12 months depending on specific clinical circumstances. Higher doses of aspirin are also generally not recommended as they may increase the risk of bleeding without providing additional